Genmab (GMAB) has received positive ratings from two major financial institutions. Truist Financial analyst Gregory Renza maintained a Buy rating on the stock and set a price target of $45.00. Renza, a 5-star analyst with an average return of 16.3% and a 52.21% success rate, covers the Healthcare sector and focuses on stocks like Amgen, MannKind, and Revolution Medicines.
In a separate report, Bank of America Securities also maintained a Buy rating on Genmab with a price target of DKK2,850.00. The ratings come on the heels of Genmab's latest earnings release for the quarter ending June 30, which showed a quarterly revenue of $1.16 billion and a net profit of $303 million. This represents growth compared to the same period last year, when the company earned $924.81 million in revenue and had a net profit of $335.93 million.